Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1: GU tumours, non-prostate

1733MO - First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer


11 Sep 2022


Mini Oral session 1: GU tumours, non-prostate


Radiological Imaging;  Staging Procedures;  Cancer Diagnostics

Tumour Site

Urothelial Cancer


Nicholas James


Annals of Oncology (2022) 33 (suppl_7): S785-S807. 10.1016/annonc/annonc1080


N.D. James1, S. Pirrie2, W. Liu3, K. Jefferson4, J. Gallagher2, A. Hughes2, A. Knight5, V. Nanton6, H.P. Mintz2, A. Pope2, H. Doyle2, J. Singh2, S. Hafeez7, P. Patel2, J. Catto8, R. Bryan9

Author affiliations

  • 1 Prostate And Bladder Cancer Research Department, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 2 Cancer Research Uk Ctu, Institute of Cancer and Genomic Sciences - University of Birmingham, B15 2SY - Birmingham/GB
  • 3 Cancer Research Uk Ctu, The Institute of Cancer and Genomic Sciences - University of Birmingham, B15 2TT - Birmingham/GB
  • 4 Urology, University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, CV2 2DX - Coventry/GB
  • 5 Patient Advocacy, Action on Bladder Cancer, GL8 8SQ - Tetbury/GB
  • 6 Medicine, University of Warwick, CV4 7AL - Coventry/GB
  • 7 Radiotherapy And Imaging, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 8 Urology Department, University of Sheffield Medical School, S10 2RX - Sheffield/GB
  • 9 Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences - University of Birmingham, B15 2SY - Birmingham/GB


Login to access the resources on OncologyPRO.

Abstract 1733MO


Transurethral resection of bladder tumour (TURBT) has been the mainstay of bladder cancer staging for a century. The objective of the trial was to assess the feasibility and efficacy of the substitution of TURBT with MRI and biopsy in the staging of patients with suspected muscle invasive bladder cancer (MIBC). The hypothesis being tested was that image directed staging would shorten time to correct treatment for MIBC patients.


Patients with suspected bladder cancer were identified via the haematuria clinic. Those with possible muscle invasive disease (assessed on a Likert scale at flexible cystoscopy) were randomised to standard TURBT assessment (Pathway 1) or MRI based assessment (Pathway 2) with tumour biopsy. Patients with probable non-muscle invasive disease (NMIBC) all underwent TURBT. Primary outcome for Feasibility Phase: proportion of patients completing allocated pathway (target 80%). Primary outcome, Efficacy Phase: time to correct treatment, defined as TURBT for NMIBC or the first of chemotherapy, radiotherapy, surgery or decision for palliative care for MIBC (target: 30 day improvement).


Between May 2018 and December 2021, 143 patients were randomised, median age 74 years, 47.9% probable NMIBC, 52.1% possible MIBC. Feasibility phase: 37/39 (95% (95% CI 83-99%)) patients with MIBC followed correct pathway. Efficacy phase: Pathway 1, median time to correct MIBC treatment 98 (95% CI 72-174) days; Pathway 2 53 (95% CI 20-89) days, hazard ratio (HR) 3.4 (95% CI 1.4-8.3). Logrank test: p-value= 0.0046. Secondary outcomes include median time to correct treatment all patients: Pathway 1 37 days, Pathway 2 31 days; HR 1.3 (95% CI 0.9-1.8).


An MRI directed pathway led to substantial shortening of time to correct treatment for MIBC patients with no detrimental effect of time to treatment for NMIBC patients. Consideration should be given to incorporation of MRI into the standard pathway for all patients with suspected invasive bladder cancer.

Clinical trial identification

ISRCTN 35296862.

Editorial acknowledgement

Legal entity responsible for the study

University of Birmingham.


NHS Health Technology Agency.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.